drugset
Drugs / Donor Hematopoietic Stem Cells
last change Sep 2023 re-read 9 days ago

Donor Hematopoietic Stem Cells

Cell therapy

Developed for
transplant rejection
Investigated by
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Northwestern University

Trials 1

today NCT00619528 · not/applicable
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
— NCT00619528 Jan 2008 → Jul 2022 immunodeficiency disease, transplant rejection Northwestern University Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Donor Hematopoietic Stem Cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT00619528 ↗
Modality Cell therapy “purified donor hematopoietic Cluster of Differentiation (CD)34+ stem cells (DHSC)” NCT00619528 ↗